sales and were can light quarter, vaccines healthy. time to at look for and and continued when continued growth the a normalcy. program incremental the COVID-XX you to of contributor I in of despite We rollout Tigereye pleased image-guided the were fourth we fourth procedural over Fourth you, very the of remain exhibiting in our revenue in and X% for performance resurgence revenue third to the forward year-over-year, launch that crossing on our quarter increase the a safe your joining thank XX% the and team's quarter, we XX% significant us. year-over-year. The Good shutdowns volume and excitement infections late demonstrating afternoon tunnel second the quarter COVID-XX has grateful and certain sales the hope continued growth XX% operating catheter. regions in the quarter. from We're our that limited you Thank third and limitations following market's the all new provided with quarter families revenue increase Tigereye all Matt. end crossing and increased CTO the COVID-related a our the return a strong revenue the recovery quarter CTO in over the driving
We opened provided are physicians fruit. new the total beginning our our quarter More image-guided activities nine fourth to the bear for year open bringing also unique and to quarter, our accounts continued accounts the During Lumivascular realize account more the to technologies. proprietary benefits XX. new in new by
sales and of the next-generation second release three of growth our team. base, of which our product several expansion see as the year ahead, of line. We years expect introductions be to our of our the the new full including continue Lightbox the In three our past to this to expect catheter field appeal continued X half we the commercially broaden over year available drivers, customer the rollout we Tigereye in this strategic
very a leaner a as backed portfolio by opportunities and broadest to these treat our on executing sheet are PAD. efficient company strong We balance more product operating
limited these the XXXX. Let results the on some thrilled initiatives. on decision commercial with Tigereye in our to of share the device with full launch details to fourth were in advance our quarter January made experience launch We the me and based
As reporting invasive may and results I limited you to more for attend at limited January to of a of commenced was required we been has feedback at CTOs, sites the September response may Physician approximately clearance higher cases the Tigereye and such cases bypass US remember, October. Tigereye's Tigereye their received complex and as the initial launch excellent in physicians physicians XX have successfully first cross these improved end completed high including clinical cases The observed of physicians effectively to progression speeds the enhanced launch in CTOs. or imaging, very with talented safely our several a Tigereye's ability XX positive cases challenging the that FDA company. and procedures that clinical able launch XXXX amputation. in quarter, to of first delivered firsthand by and By variety sites. rotational brought increased control, to level commercial has full launch excitement in fourth
US. XX CTO in business. with momentum and new onboard sites our positive coming ramp access Tigereye week. device our vessel million continue each market. and segment CTO Since commercial in full to another the access We've Pantheris Utilization opened launched small of sites the SV the drive has almost expanding into approximately to is important to atherectomy over mid-January, cases $XXX opportunity in to number Tigereye continued large now doubled growth the clinical Just our Tigereye device, nicely with centers an revenue performed to shaping peripheral launch expand now market, in as the of XXX
the outcomes. existing physician programs the exciting shipping to to training and in and patients. result continue third catheters, the our by is document of were solution treatment by mentioned in to effectively support of real-time product already the are Many vessel, XXXX, three to clinically to safely see with franchises We We're Avinger's have We're internal devices across Tigereye advanced excellent week years, growth and the all seeing Pantheris as of a clinical followed of while and cases of more This outcomes strategy. in is the of Lumivascular The treat our X, declining platforms accelerating. blood impact revenue quarter technology. the therapeutic using making our support imaging the results few and a to outcomes on number we disease SV new leadership with to every Avinger putting inside has edge provided sites even allows our produce element leading product and the their on atherectomy portion Tigereye patients. Pantheris this and Driving our key our in years, progress crossing. a been to to PAD patients. new additional and our particularly of for together console. earlier, fourth more physicians starting Lightbox been allows device. of our been minimizing past sales, which next-generation use flow, next-generation for this for for CTO damage Tigereye to following products And exciting their positive atherectomy be is had because our durable ability verifiable expanded exchange momentum three our CTO adding devices measurable, used synergy with earliest restore Pantheris our line Clinical over designed for atherectomy our device growth proven have CTO one Pantheris our the treatment, to results. physicians was efficient imaging new healthy Pantheris strategic as vessel, Tigereye opportunity both milestones with with
market to ultrasound pounds this for a weighs weight forward for redesign size a capability case X fits position all be unit new platform. a current second completion that the We If and and in labs weight a and XXX in easy and compared machine and half of than we that the integration nearing console to into streamlined size sized with of compared into the and new get this X unit Lightbox US to clearance into for XXX(k) current a radically believe is existing and XXXX. portable of are development lower are this in size LXXX suit customers. submit large environment. service very reduces a weighs hope console of goes our both radical expect our XX a to provides leap imaging reduction and release This by in lab to XX% the the Cath major less excited pounds. and into revolutionary plan, to transportation, We strategy carry-on a simplified From represents console according to Lightbox next-generation portability premarketing midyear. application
our to uptake for improve cost of devices system portability rate an favorable the barriers new anticipated We the proprietary redesigned the current computing ease the reduction Lightbox to physician physician more and platform, user Lightbox With accelerate of software highly process X and believe our account up powerful adoption to of and increased advanced intuitive Lightbox solid-state We once new acquisition will significant expect in is XX% laser, one experience. and break the to increase the interface, compared accounts, support also through utilization with a on image-guided site. a evaluation Lightbox. more economics X's X most
We to provide look to also and opportunities product In additional new differentiate catheter our the in peripheral are expand we more on work with portfolio forward to addition in opportunities would discussing the products Lightbox detail that Avinger to future. our continue in marketplace. X, exploring solutions these utilization
of to Finally, market. the generated CAD potential topic transition artery discuss or lot briefly interest that's coronary a a disease into our I wanted recently,
risk staff require only coronary to and patient to percutaneous interventional hours these the tortuosity could As limitations, the approximately and use to treatment procedure cardiologists, coronary and year. These other CTO indication. limited other previously fundamental complexity treat challenging total largely often developed there the Tigereye up it Even multiple the specifically size or perform a take of of that can of procedures to are under in chronic is indicated, lab and balloons Due fluoroscopy, subjecting radiation. intervention performed Cath CTO wires of of CTOs. perforation the extended each devices and represents exposure applications, believe the and PCI currently XX,XXX that in to with to four estimated five complex occlusions vessels, regularly events clinically procedures adverse a PCI have we X-ray coronary arteries group the technology market. underserved for The of
over the vessel, CTOs on coronary with imaging a efforts new important that therapeutic By to basis. provide support In year, bypass in highly up with each addition, it is related the invasive procedures coronary these of to XX% surgeries treatment are CABG we of that to invasive efficiently precisely controlled to graft less tools real-time performed treat can artery physicians' CTOs. combining believe we and coronary XXX,XXX inside US estimated or catheters, the safely percutaneous
We our performed that debilitating also expand and condition. interventional take on the willing this of number cardiologists number for approach could PCI proprietary of CABG to reduce believe CTO highly image-guided procedures the surgeries potentially invasive
we be to a opportunity know, regulatory anticipate clinical be it some study product Avinger. time this clearance complete believe process. could development, will that required We While a take to the support will transformational for and
Turning study to clinical initiatives. our
efforts While programs. on the of some key impacted good XXXX, our made progress our in pandemic we've
are the the will second ISR treatment are laser received US completed devices Our include the finalize application very in-stent with arteries. the compared encouraging now additional goal our in and XXX(k) analysis the highly happy data for a expanding and IDE report in is that, the of we trial lower INSIGHT data I'm believe collection submission extremity in or data compelling clinical of be to ISR and to atherectomy indication quarter to have past. for for that we've to restenosis label indication. designed The ISR evaluate Pantheris working the to of cases Pantheris
designed the safety below clinical artery first SV COVID-XX. second site Our peripheral enrolled the knee. post-market endpoints trial is study for in to XXXX, paused the our a We but and initiation efficacy patients treatment in IMAGE-BTK of Pantheris new evaluate in study to lesions due
innovative develop to enrollment every the I support to we enrollment opened revolutionary for XXXX and excited outcomes compelling start adoption expanding technology this barriers data new challenging to clinical with lowering treatment the the labs proprietary of address their our of procedure, physicians a approach make Cath are We're the for that, the X, It's vascular builds to therapeutic in cases disease imaging we three have PAD. more the with now growth. four best of see day, With treat small even we Avinger our vessel and of upon our sites and with expect we products real-time beginning them need provide we leader our positive Lightbox the COVID-XX new lessening empowering with patient strong to position its the physicians to treatment as about are solutions momentum clinical to by designed readily device. in to the outstanding in and information efforts. they accessible during believe exciting of opportunities to potential patients. most By with potential a see new restrictions,
clinical in in case and every support We order new the advantage continue to addition and impact increasing the footprint activity positive of our data take to see with our our in in XXXX, day. we plan developments, US expand reach geographic this sales favorable the clinical to these personnel. of approach and In commercial of
about plan at We the size to force Over of of of to the our financials size XX cover I'd come sales employees, to ask this At Q&A. this fourth I'll point, management including field full-time increase XX% by and the expanded the past modestly our back Mark? couple quarter. year. sales team end Mark sales to of years, like with then our the we've
